Drug Profile

Desmethyl cariprazine prodrug - Abbvie

Alternative Names: ABBV-932; RGH-932

Latest Information Update: 20 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AbbVie
Developer AbbVie; Gedeon Richter
Class Antidepressants; Anxiolytics; Mood stabilisers; Small molecules
Mechanism of Action Dopamine D2 receptor partial agonists; Dopamine D3 receptor partial agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

17 Jun 2025 AbbVie plans phase-I pharmacokinetics and safety trial (In volunteers) in August 2025 (PO, Capsule) (NCT07024797)
26 May 2025 AbbVie completes the phase-I Ph1PET UK trial in Bipolar disorders (In volunteers) in United Kingdom (PO) (NCT06300580)
26 May 2025 AbbVie completes the phase-I Ph1PET UK trial in Generalised anxiety disorder (In volunteers) in United Kingdom (PO) (NCT06300580)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com